Modeling-error Robustness of a Viral-load Preconditioning Strategy for HIV Treatment Switching

Overview

Journal Proc Am Control Conf

Date 2014 Jun 24

PMID 24954972

Citations 5

Authors

Rutao Luo

Michael J Piovoso

Ryan Zurakowski

Affiliations

Soon will be listed here.

Abstract

In previous work, we have developed optimal-control based approaches that seek to minimize the risk of subsequent virological failure by "pre-conditioning" the viral load during therapy switches. In this paper, we use Monte-Carlo methods to evaluate the sensitivity of an open-loop implementation of these approaches to modeling errors. To account for hidden parameter dependencies, we use parameter distributions obtained from the convergence of Bayesian parameter estimation techniques applied to sets of clinical data obtained during serial therapy interruptions as the distribution from which the Monte-Carlo method samples.

Citing Articles

Approximate-model closed-loop minimal sampling method for HIV viral-load minima detection.

Zurakowski R, Churgin M, Perez C, Rodriguez M Proc Am Control Conf. 2012; :5418-5419.

PMID: 23001383 PMC: 3445656. DOI: 10.1109/acc.2011.5991281.

Robust closed-loop minimal sampling method for HIV therapy switching strategies.

Cardozo E, Zurakowski R IEEE Trans Biomed Eng. 2012; 59(8):2227-34.

PMID: 22652153 PMC: 3467342. DOI: 10.1109/TBME.2012.2201479.

Optimal antiviral switching to minimize resistance risk in HIV therapy.

Luo R, Piovoso M, Martinez-Picado J, Zurakowski R PLoS One. 2011; 6(11):e27047.

PMID: 22073250 PMC: 3207836. DOI: 10.1371/journal.pone.0027047.

Nonlinear observer output-feedback MPC treatment scheduling for HIV.

Zurakowski R Biomed Eng Online. 2011; 10:40.

PMID: 21619634 PMC: 3127993. DOI: 10.1186/1475-925X-10-40.

Controlling the Evolution of Resistance.

Luo R, Cannon L, Hernandez J, Piovoso M, Zurakowski R J Process Control. 2011; 21(3):367-378.

PMID: 21516198 PMC: 3079266. DOI: 10.1016/j.jprocont.2010.11.010.

References

Perrin L, Telenti A . HIV treatment failure: testing for HIV resistance in clinical practice. Science. 1998; 280(5371):1871-3. DOI: 10.1126/science.280.5371.1871. View

Ribeiro R, Bonhoeffer S . Production of resistant HIV mutants during antiretroviral therapy. Proc Natl Acad Sci U S A. 2000; 97(14):7681-6. PMC: 16603. DOI: 10.1073/pnas.97.14.7681. View

Martinez-Cajas J, Wainberg M . Antiretroviral therapy : optimal sequencing of therapy to avoid resistance. Drugs. 2007; 68(1):43-72. DOI: 10.2165/00003495-200868010-00004. View

Mangel W, McGrath W, Brown M, Baniecki M, Barnard D, Pang Y . A new form of antiviral combination therapy predicted to prevent resistance from arising, and a model system to test it. Curr Med Chem. 2001; 8(8):933-9. DOI: 10.2174/0929867013372742. View

Ruiz L, Carcelain G, Martinez-Picado J, Frost S, Marfil S, Paredes R . HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS. 2001; 15(9):F19-27. DOI: 10.1097/00002030-200106150-00001. View

Huang Y, Liu D, Wu H . Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system. Biometrics. 2006; 62(2):413-23. PMC: 2435289. DOI: 10.1111/j.1541-0420.2005.00447.x. View

Yeni P, Hammer S, Hirsch M, Saag M, Schechter M, Carpenter C . Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004; 292(2):251-65. DOI: 10.1001/jama.292.2.251. View

Hammer S, Saag M, Schechter M, Montaner J, Schooley R, Jacobsen D . Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006; 296(7):827-43. DOI: 10.1001/jama.296.7.827. View

Yeni P, Hammer S, Carpenter C, Cooper D, Fischl M, Gatell J . Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002; 288(2):222-35. DOI: 10.1001/jama.288.2.222. View

10.

Sungkanuparph S, Anekthananon T, Hiransuthikul N, Bowonwatanuwong C, Supparatpinyo K, Mootsikapun P . Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai. 2009; 91(12):1925-35. View

11.

Bonhoeffer S, Nowak M . Pre-existence and emergence of drug resistance in HIV-1 infection. Proc Biol Sci. 1997; 264(1382):631-7. PMC: 1688415. DOI: 10.1098/rspb.1997.0089. View

12.

Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat M, Marfil S . Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS. 2000; 14(4):397-403. DOI: 10.1097/00002030-200003100-00013. View

13.

Hirsch M, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes D, DAquila R . Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003; 37(1):113-28. DOI: 10.1086/375597. View

14.

Finzi D, Hermankova M, Pierson T, Carruth L, Buck C, Chaisson R . Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278(5341):1295-300. DOI: 10.1126/science.278.5341.1295. View

15.

Hirsch M, Brun-Vezinet F, DAquila R, Hammer S, Johnson V, Kuritzkes D . Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 2000; 283(18):2417-26. DOI: 10.1001/jama.283.18.2417. View

16.

Hirsch M, Gunthard H, Schapiro J, Brun-Vezinet F, Clotet B, Hammer S . Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008; 47(2):266-85. DOI: 10.1086/589297. View